Corient Private Wealth LLC Purchases 390,000 Shares of Nautilus Biotechnology, Inc. $NAUT

Corient Private Wealth LLC raised its position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 860.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 435,350 shares of the company’s stock after purchasing an additional 390,000 shares during the period. Corient Private Wealth LLC’s holdings in Nautilus Biotechnology were worth $316,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NAUT. Presidio Capital Management LLC raised its position in shares of Nautilus Biotechnology by 246.6% during the 2nd quarter. Presidio Capital Management LLC now owns 34,664 shares of the company’s stock valued at $25,000 after purchasing an additional 24,664 shares during the period. Callan Family Office LLC bought a new stake in Nautilus Biotechnology during the second quarter valued at about $35,000. Bank of America Corp DE lifted its position in shares of Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock valued at $83,000 after acquiring an additional 13,363 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Nautilus Biotechnology by 145.2% in the first quarter. Deutsche Bank AG now owns 54,839 shares of the company’s stock worth $47,000 after acquiring an additional 32,470 shares during the period. Finally, Acadian Asset Management LLC grew its position in shares of Nautilus Biotechnology by 468.3% during the first quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after purchasing an additional 50,871 shares in the last quarter. 50.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on NAUT shares. Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell” and a consensus price target of $2.50.

Nautilus Biotechnology Trading Down 1.5%

NASDAQ:NAUT opened at $1.91 on Wednesday. The company has a market capitalization of $241.25 million, a P/E ratio of -3.82 and a beta of 1.48. Nautilus Biotechnology, Inc. has a 12 month low of $0.62 and a 12 month high of $2.54. The business’s 50-day moving average is $1.85 and its 200 day moving average is $1.15.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Monday, October 27th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. On average, research analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.